

PROF.DR.SİNEM CİVRİZ BOZDAĞ

Doğum tarihi:04.07.1978

Lise:TED Ankara Koleji,1994

Yabancı Dil: İngilizce

Yüksek lisans:Ankara Üniversitesi Tıp Fakültesi,1994-2000

Ana dal ihtisas:İç Hastalıkları A.B.D, Ankara Üniversitesi Tıp Fakültesi,2000-2005

Yan dal ihtisas:Hematoloji B.D, Ankara Üniversitesi Tıp Fakültesi,2007-2011

Yurt dışı deneyimi: 10.2011-02.2012 Thomas Jefferson Üniversitesi,ABD

Mecburi hizmet deneyimi: Ankara Onkoloji Hastanesi Hematoloji B.D, 2012-2014

Doçentlik ünvanı: Hematoloji B.D, Ankara Üniversitesi Tıp Fakültesi ,09.2014

Yabancı Dil Sınavı:81,25

ULUSLARARASI MAKALELER:

1-Narlı Özdemir Z, Kırçalı E, Sahin U, Seval GC, Civriz Bozdog S et al. Pretransplant consolidation therapies improve the outcome of myeloablative allogeneic transplantation in Adults with Ph- acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2022.

2-Cengiz Seval G, Sahin U, Civriz Bozdog S, Kurt Yüksel M,Nisa Akay et al. Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides. Dermatol Therapy 2022.

3-Civriz Bozdağ S, Seval GS, Hindilerden İY, Hindilerden F et al. Clinical characteristics and outcome of COVID -19 in Turkish hematological malignancy patients. TJH-2021.

4-Zeiser R,Polverelli N, Ram R, Hashmi S et al. Ruxolitinib for chronic GVHD. NEJM 2021.

5-Paydaş S, Laçın S, Doğan M, Barista I et al. IPS-3 Validation in 1012 cases with classical Hodgkin lymphoma.Leuk Res 2021.

- 6- Paydas S, Laçın S, Doğan M, Barista I, Yıldız B et al. Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma. *Leuk Res* 2021.
- 7- Akay OM, Ozbakaj M, Pehlivan M, Yiğenoğlu TN. Brentuximab vedotin consolidation therapy after autologous stem cell transplantation in patients with high risk Hodgkin Lymphoma. *Hematology Oncology* 25 Jun 2021.
- 8- Narlı Özdemir Z, Cengiz Seval G, Sahin U, Uslu A, Gunduz M. Blastic plasmacytoid dendritic cell neoplasm: single center experience on a Rare Hematological malignancy. *Indian J Hematol Blood* 2021.
- 9- Narlı ZO, Ugur S, Dalva K, Uslu A, Ozturk C et al. Highlighting the Prognostic Importance of Measurable Residual Disease Amongst Acute Myeloid Leukemia Risk Factors. *TJH* 2021.
- 10- Yılmaz F, Soyer N, Seval G, Civriz Bozdog S, Topcuoğlu P et al. Hematopoietic stem cell transplantation for patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic anemia. *TJH* 2021.
- 11- Eroğlu D, Dalva K, Kalacı E, Toprak S, Bozdog SC et al. Prospective Follow up of panel reactive antibodies until completion of therapy including allogeneic stem cell transplantation among patients with Acute leukemia. *Exp Clin Transp* 2021.
- 12- Kumbasar H, Duman B, Yüksel M, Civriz Bozdog S, Kılıç P et al. Stem cells and Psyche: Perspectives and a review of literature. *Journal of oncological sciences*, 2020.
- 13- Narlı Özdemir, Civriz Bozdog S. Hematological malignancies and fertility. *Exp med biol* 2020.
- 14- Ataca Atilla P, Akkuş E, Atilla E, Civriz Bozdog S et al. Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation. *Clinical Transplantation*, 2020.
- 15- Ataca Atilla P, Akkuş E, Atilla E, Civriz S et al. Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. *Transfusion Clinique et Biologique*, 2020.
- 16- Zeiser R, von Buffnagel N, Butler J, Mothay M, Niederwieser D, Or R et al. Ruxolitinib for

Glucocorticoid-Refractory Acute Graft-versus-Host Disease. New England Journal of Medicine 2020.

17-Ozkan E, Soydal C, Sahin U, Beksac M,Ozturk C, Bozda SC ET AL.Evaluation of chemokine receptor -4 expression by 68Ga Pentixafor PET/CT in patients with Multipl myeloma.UHOD 2019.

18-Atilla E ,Sahin U, Atilla P, Merter M,Özyürek E,Ceyhan K, Bozdag SC. Allogeneic stem cell transplantation for relapsed primary central nervous system:Is it feasible?Hematol Oncol Stem cell Therapy 2019.

19-Atilla E, Yalciner M,Ataca P,Ateş C,Civriz Bozdag S et al.Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?. Antiviral Therapy 2018.

20-Durdu MS,Cakici ,Gümüş F,Çubukcuoğlu G,Civriz Bozdag SC,Özçınar E et al. Promising utilization areas of therapeutic plasmapheresis in cardiovascular T surgery practice. TRASCI, 2018.

21-Özdemir ZN,Civriz Bozdag SC.Graft failure after allogeneic hematopoietic stem cell transplantation.TRASCI 2018.

22- Narlı Özdemir Z, Sahin U, Bozdag SC,İlhan O. Multiple arterial thrombosis related with Cantharidian ingestion.Case Rep Hematol 2018.

23-Atilla E,Eroğlu D, Ataca P, Dolapçı I,Tekeli F,Civriz Bozdag S et al. Upper respiratory viral infections in patients with haematological malignancies after allogeneic haematopoietic stem cell transplantation: a retrospective study. Antiviral therapy 2018.

24-Bozdag SC,Kurt Yüksel M,Demirer T.Adult stem cells and medicine. Adv Exp Med Biol 2018.

25-Ataca P, Atilla E, Civriz Bozdag S, Yüksel M,Koçak SK et al.Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience. Hematology/Oncology and Stem Cell Therapy 2017.

26-Atilla E, Ataca P, Civriz Bozdag S, Yüksel M, Toprak SK et al.Extracorporeal photochemotherapy in mycosis fungoides.TRASCI 2017.

27-Atilla E,Ataca P,Civriz Bozdag S, Yüksel M, Toprak SK et al. (2017). Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS). International Journal of Hematology, 2017. [L]
[SEP]

28-^[1]^[SEP]Atilla E, Toprak SK, Civriz Bozdog S, Topcuoplu P, Arslan Ö. A Randomized Comparison of Hemoglobin Content-Based Versus Standard (Unit- Based) Red Blood Cell Transfusion Policy. Turkish Journal of Hematology 2017.

29-Gündüz M, Özen M, Şahin U, Toprak SK, Civriz Bozdog S et al. Subsequent malignancies after allogeneic hematopoietic stem cell transplantation. Clinical Transplantation 2017.

^[1]^[SEP]30-Ataca Atilla P, Atilla E, Edipoglu Elif, Civriz Bozdog S et al. Fertility after Allogeneic Hematopoietic Stem cell transplantation A 23 year review from a Tertiary Hospital. International Journal of Hematology and Oncology 2016.

31-Civriz Bozdog S, Tekgündüz E, Altuntas F. Treatment of acute graft versus host disease with mesenchymal stem cells Questions and answers. Transfus Apher Sci 2016.

32-Tekgündüz E, Kaya Ali H, Civriz Bozdog S, Koçubaba S et al. Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation. Transfus Apher Sci, 2016.

33-Özen mehmet,, Civriz Bozdog S, Çakmak G, Topcuoğlu P, Eroğlu AH, Gündüz M et al. Antilymphocyte thymocyte globulin for the treatment of steroid refractory acute graft versus host disease 20 year experience at a single center. international journal of hematology and oncology 2015.

34- Civriz Bozdog S, Tekgündüz E, Altuntas F The current status in hematopoietic stem cell mobilization. TRANSFUSION AND APHERESIS SCIENCE 2015. ^[1]^[SEP]

35-Esbah O, Tekgündüz E, Şirinoğlu I, Civriz Bozdog S, Kaya Ali H et al. Finding The Optimal Conditioning Regimen For Relapsed Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation A Retrospective Comparison Of Beam And High Dose Ice. TJH 2015.

36- Civriz Bozdog S , İlhan O. Peripheral blood stem cell mobilization and collection from elderly patients and elderly healthy donor. TRASCI 2015. ^[1]^[SEP]

37- Civriz Bozdog S, Tekgündüz emre, Durgun gamze, Sarıca A et al. Which regimen is better for stem cell mobilization of lymphoma patients. TRASCI 2013. ^[1]^[SEP]

38-Budak alpdogan T ,sauter C ,bailey C ,biswas c, panis m, Civriz Bozdog Haploidentical hematopoietic SCT increases graft versus tumor effect against renal cell carcinoma. BMT 2013.

39- Demiriz I, Civriz Bozdog S, emre tekgündüz E, uğur bilge ,durgun gamze, koçubaba şerife, ALTUNTAŞ FEVZİ (2013). Predicting the successful peripheral blood stem cell harvesting. Transfusion and Apheresis Science, 48(3), 411-414.

40-Namdaroğlu S, Tekgündüz E, Civriz Bozdog S, Durgun G, Sarıca Ali et al. Microbial contamination of hematopoietic progenitor cell products. Transfusion and Apheresis Science 2013. ^[1]^[SEP]

41- Civriz Bozdog S,Bay M,Ayyıldız E,Topçuoğlu P,İlhan O. Older age and capacity of colony forming unit in autologous peripheral derived hematopoietic cells. Transfusion and Apheresis Science 2012.

42- Civriz Bozdog S,Bay M,Ayyıldız E,Topçuoğlu P,İlhan O . Impact of age and diagnosis on viability during centrifugation and cryopreservation of peripheral blood stem cell products. Transfusion and Apheresis Science 2012.

KİTAP BÖLÜMLERİ:

1-Progres in stem cell transplantation (Hematopoietic stem cell source and storage)-2015

2-Progres in stem cell transplantation(Use of monoclonal antibodies in conditioning regimen in Transplantation)-2015

3- Türkiye Klinikleri HEMATOLOJİ-ÖZEL KONU Kronik GVHH risk faktörleri ve biyobelirteçleri-2019

4-Türkiye Klinikleri HEMATOLOJİ-ÖZEL KONU COVID ile yükselen teletıp ve Hematoloji-2020

5-Hematolog(Hematopoietik kök hücre nakli sayısı)-Allojeneik hematopoietik kök hücre naklinde graft versus host hastalığı-2019

YÖNETİLEN TEZLER:

1-HAYZARAN EDİP, (2020). Akut myeloblastik lösemi hastalarında nükleofosmin mutasyonu minimal rezidüel hastalık takibinde yol gösterici midir?, Ankara Üniversitesi->Tıp Fakültesi->İç Hastalıkları Ana Bilim Dalı

2-KALACI ENDER, (2018). Allojenik hematopoietik kök hücre nakli yapılan akut lenfoblastik lösemi hastalarında sitomegalovirüs enfeksiyonunun nakil sonuçlarına etkileri, Ankara Üniversitesi->Tıp Fakültesi->İç Hastalıkları Ana Bilim Dalı

3-AYŞEN GÖRÜNMEZOĞLU, (2021). , Allojeneik kök hücre nakli sonrasında Gastrointestinal Sistemi tutan akut ve kronik graft versus host hastalığı(GVHH) geliştiren hastalarda tanı anında ve GVHH tedavisi sonrası, Ankara Üniversitesi->Tıp Fakültesi->İç Hastalıkları Ana Bilim Dalı

ATIF SAYISI:565

H INDEX :7

YÜRÜTÜLEN KLİNİK ARAŞTIRMALAR:

1-Allojeneik nakil hastalarında CMV profilaksisi için letermovir, Faz 3 2015 – 2017 Sorumlu Araştırmacı

2-Allogeneic kök hücre naklinden sonra kortikosteroide dirençli akut graft versus host hastalığı görülen hastalarda en iyi mevcut tedaviye karşı ruxsolutinibin kullanıldığı, faz II, randomize, açık etiketli, çok merkezli çalışma REACH 2- 2018 – Sorumlu Araştırmacı

3-Allojenik transplantasyonda ve AML hastalarında antifungal profilaksi, Retrospektif 2018- Sorumlu Araştırmacı

4-Allojenik kök hücre transplantasyonundan sonra kortikosteroide refrakter kronik graft versus host hastalığı bulunan hastalarda en iyi mevcut tedaviye karşılık ruxsolutinibi değerlendiren, faz III, randomize, açık etiketli, çok merkezli çalışma REACH 3 2019- Sorumlu Araştırmacı

5-KMML-2 ve orta-yüksek risk MDS hastalarında MBG453 tedavisi-2021-- Sorumlu Araştırmacı

